PODCAST | Finance

2Q public markets preview & AACR takeaways: BioCentury’s latest podcast

Plus: How degrader-antibody conjugates are building on the success of the ADC paradigm

April 8, 2024 11:52 PM UTC

M&A has been driving a recovery for biotech, with $62 billion in takeouts in the past six months restocking specialist investors’ coffers for their next wave of investments. On the latest BioCentury This Week podcast, BioCentury’s editors assess the state of the public markets heading into the second quarter, including the outsize role PIPEs have had in financing industry’s comeback.

They also discuss their takeaways from analyzing nearly 7,000 abstracts from the American Association for Cancer Research, which kicked off on Friday, as well as the editors’ insights on why degrader-antibody conjugates are emerging as the next contenders to build on the success of the antibody-drug conjugates paradigm.

Editor in Chief Simone Fishburn also previews Grand Rounds, BioCentury’s first R&D conference, which will focus on the biotech industry’s interface with academia, bringing together decision-makers and the next innovators in Nashville Sept. 9-11. 

To learn more about BioCentury Grand Rounds and opportunities to present, see the conference website. For information on sponsoring The BioCentury Show and the BioCentury This Week podcast, please email